文献速递临床试验与 GCP

德谷胰岛素对比甘精胰岛素U100对1型糖尿病患者低血糖的影响:SWITCH 1随机临床试验

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01

这项双盲随机交叉非劣效性试验纳入501例至少有一种低血糖危险因素的1型糖尿病成人患者,在美国84个中心和波兰6个中心进行两个32周治疗期。维持期内,德谷胰岛素组总体症状性低血糖发生率为每100人年暴露2200.9次,甘精胰岛素U100组为2462.7次,率比0.89(95%CI 0.85-0.94),非劣效和优效检验P均<.001。

要点

  • 德谷胰岛素总体症状性低血糖发生率低于甘精胰岛素U100,率比0.89(95%CI 0.85-0.94)。
  • 德谷胰岛素夜间症状性低血糖发生率低于甘精胰岛素U100,率比0.64(95%CI 0.56-0.73)。
  • 维持期内德谷胰岛素组严重低血糖患者比例10.3% vs 甘精胰岛素U100组17.1%,风险差-6.8%。

核心结论

  • 在至少有一种低血糖危险因素的1型糖尿病患者中,德谷胰岛素治疗32周相比甘精胰岛素U100降低了总体症状性低血糖发作率。

研究设计与样本

  • 双盲、随机、交叉非劣效性试验,纳入501例至少有一种低血糖危险因素的1型糖尿病成人患者,在美国84个中心和波兰6个中心于2014年1月至2016年1月12日进行。
  • 患者按1:1随机接受每日一次德谷胰岛素后序贯甘精胰岛素U100(n=249)或甘精胰岛素U100后序贯德谷胰岛素(n=252),每个治疗序列内再按1:1随机分配早晨或晚间给药。
  • 治疗包括两个32周治疗期,每个治疗期含16周剂量调整期和16周维持期。

主要发现

  • 维持期内总体症状性低血糖发生率为德谷胰岛素组每100人年暴露2200.9次 vs 甘精胰岛素U100组每100人年暴露2462.7次,率比0.89(95%CI 0.85-0.94;非劣效P<.001;优效P<.001;率差-130.31次每100人年暴露,95%CI -193.5至-67.16)。
  • 维持期内夜间症状性低血糖发生率为德谷胰岛素组每100人年暴露277.1次 vs 甘精胰岛素U100组每100人年暴露428.6次,率比0.64(95%CI 0.56-0.73;非劣效P<.001;优效P<.001;率差-61.94次每100人年暴露,95%CI -83.85至-40.03)。
  • 维持期内发生严重低血糖的患者比例德谷胰岛素组为10.3%(95%CI 7.3%-13.3%)vs 甘精胰岛素U100组为17.1%(95%CI 13.4%-20.8%),McNemar P=.002;风险差-6.8%(95%CI -10.8%至-2.7%)。
  • 501例随机患者平均年龄45.9岁,男性占53.7%,395例(78.8%)完成试验。

关键数值与推荐

  • 主要终点为非劣效性,标准为率比双侧95%CI上限不超过1.10;若确立非劣效则进行双侧优效性检验。
  • 主要终点为维持期内总体严重或血糖确认(<56 mg/dL)的症状性低血糖发作率。
  • 次要终点包括维持期内夜间症状性低血糖发作率和发生严重低血糖的患者比例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Hypoglycemia, common in patients with type 1 diabetes, is a major barrier to achieving good glycemic control. Severe hypoglycemia can lead to coma or death. OBJECTIVE: To determine whether insulin degludec is noninferior or superior to insulin glargine U100 in reducing the rate of symptomatic hypoglycemic episodes. DESIGN, SETTING, AND PARTICIPANTS: Double-blind, randomized, crossover noninferiority trial involving 501 adults with at least 1 hypoglycemia risk factor treated at 84 US and 6 Polish centers (January 2014-January 12, 2016) for two 32-week treatment periods, each with a 16-week titration and a 16-week maintenance period. INTERVENTIONS: Patients were randomized 1:1 to receive once-daily insulin degludec followed by insulin glargine U100 (n = 249) or to receive insulin glargine U100 followed by insulin degludec (n = 252) and randomized 1:1 to morning or evening dosing within each treatment sequence. MAIN OUTCOMES AND MEASURES: The primary end point was the rate of overall severe or blood glucose-confirmed (<56 mg/dL) symptomatic hypoglycemic episodes during the maintenance period. Secondary end points included the rate of nocturnal symptomatic hypoglycemic episodes and proportion of patients with severe hypoglycemia during the maintenance period. The noninferiority criterion for the primary end point and for the secondary end point of nocturnal hypoglycemia was defined as an upper limit of the 2-sided 95% CI for a rate ratio of 1.10 or lower; if noninferiority was established, 2-sided statistical testing for superiority was conducted. RESULTS: Of the 501 patients randomized (mean age, 45.9 years; 53.7% men), 395 (78.8%) completed the trial. During the maintenance period, the rates of overall symptomatic hypoglycemia were 2200.9 episodes per 100 person-years' exposure (PYE) in the insulin degludec group vs 2462.7 episodes per 100 PYE in the insulin glargine U100 group for a rate ratio (RR) of 0.89 (95% CI, 0.85-0.94; P < .001 for noninferiority; P < .001 for superiority; rate difference, -130.31 episodes per 100 PYE; 95% CI, -193.5 to -67.16). The rates of nocturnal symptomatic hypoglycemia were 277.1 per 100 PYE in the insulin degludec group vs 428.6 episodes per 100 PYE in the insulin glargine U100 group, for an RR of 0.64 (95% CI, 0.56-0.73; P < .001 for noninferiority; P < .001 for superiority; rate difference, -61.94 episodes per 100 PYE; 95% CI, -83.85 to -40.03). A lower proportion of patients in the insulin degludec than in the insulin glargine U100 group experienced severe hypoglycemia during the maintenance period (10.3%, 95% CI, 7.3%-13.3% vs 17.1%, 95% CI, 13.4%-20.8%, respectively; McNemar P = .002; risk difference, -6.8%; 95% CI, -10.8% to -2.7%). CONCLUSIONS AND RELEVANCE: Among patients with type 1 diabetes and at least 1 risk factor for hypoglycemia, 32 weeks' treatment with insulin degludec vs insulin glargine U100 resulted in a reduced rate of overall symptomatic hypoglycemic episodes. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02034513.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Lane W, Bailey TS, Gerety G, et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial. JAMA. 2017. PMID: 28672316. doi:10.1001/jama.2017.7115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。